Shigella Sonnei 53G Human Infection Study in Kenyan Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

August 30, 2027

Conditions
Shigellosis
Interventions
BIOLOGICAL

Shigella sonnei 53G

Lyophilized S. sonnei 53G strain (Lot 1794)

DRUG

Ciprofloxacin 500 mg

Ciprofloxacin (500 mg orally twice daily for three days),

Trial Locations (1)

80108

RECRUITING

KEMRI-Wellcome Trust Research Programme, Kilifi

Sponsors
All Listed Sponsors
collaborator

KEMRI-Wellcome Trust Collaborative Research Program

OTHER

collaborator

KEMRI United States Army Medical Research Directorate-Kenya

UNKNOWN

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

Naval Medical Research Center

FED

collaborator

PATH

OTHER

collaborator

Johns Hopkins University

OTHER

lead

University of Oxford

OTHER